pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
EstroTep 500 MBq/mL, solution injectable
Phase 3 · small molecule · Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor
EstroTep 500 MBq/mL, solution injectable for Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor is a Phase 3 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Internal code IC 2022-12
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The George Institute
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor
- Status
- active
- Trials
- 1